Mitsubishi UFJ Trust & Banking Corp trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 5.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 588,337 shares of the medical device company’s stock after selling 35,538 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.15% of DexCom worth $81,585,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in DXCM. Dynamic Advisor Solutions LLC bought a new stake in shares of DexCom in the fourth quarter valued at about $260,000. Raymond James Trust N.A. boosted its position in DexCom by 333.6% during the 4th quarter. Raymond James Trust N.A. now owns 22,099 shares of the medical device company’s stock worth $2,742,000 after acquiring an additional 17,002 shares during the last quarter. FORVIS Wealth Advisors LLC grew its stake in shares of DexCom by 0.7% during the 4th quarter. FORVIS Wealth Advisors LLC now owns 16,381 shares of the medical device company’s stock worth $2,033,000 after acquiring an additional 110 shares in the last quarter. Advisor Resource Council raised its holdings in shares of DexCom by 586.6% in the fourth quarter. Advisor Resource Council now owns 17,427 shares of the medical device company’s stock valued at $2,163,000 after purchasing an additional 14,889 shares during the last quarter. Finally, CX Institutional bought a new stake in shares of DexCom in the fourth quarter worth $286,000. 97.75% of the stock is owned by institutional investors.
Insider Buying and Selling at DexCom
In other news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at $2,878,378.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the firm’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 4,112 shares of company stock valued at $480,861 in the last quarter. Company insiders own 0.30% of the company’s stock.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on DXCM
DexCom Stock Performance
Shares of DexCom stock traded up $0.96 on Friday, hitting $111.66. The stock had a trading volume of 2,274,469 shares, compared to its average volume of 2,634,305. The stock has a market cap of $44.40 billion, a price-to-earnings ratio of 72.04, a price-to-earnings-growth ratio of 2.73 and a beta of 1.16. The business’s 50 day moving average is $118.01 and its two-hundred day moving average is $124.61. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.
DexCom (NASDAQ:DXCM – Get Free Report) last posted its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. Analysts forecast that DexCom, Inc. will post 1.78 EPS for the current year.
DexCom Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Read More
- Five stocks we like better than DexCom
- What is Put Option Volume?
- Why This AI Stock is Rising Despite Tech Sell-Off
- How Technical Indicators Can Help You Find Oversold Stocks
- Investors Are Moving into Bonds and Small Cap Stocks: Here’s Why
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 7/15 – 7/19
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.